References
- Hu Y, Liu Y, Pelletier S, et al. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet 2004;36:453–461.
- Porkka K, Koskenvesa P, Lundan T, et al. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood 2008;112: 1005–1012.
- Manabe A, Kawasaki H, Chin M, et al. A brief use of imatinib immediately before hematopoietic stem cell transplantation (HSCT) in children with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL). Results of the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) study Ph+ ALL04. Blood 2011;118(Suppl. 1): Abstract 2554.
- Thomas DA, Faderl S, Cortes J, et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 2004;103:4396–4407.
- Schultz KR, Bowman WP, Aledo A, et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. J Clin Oncol 2009;27:5175–5181.
- Ono T, Miyawaki S, Kimura F, et al. BCR-ABL1 mutations in patients with imatinib-resistant Philadelphia chromosome- positive leukemia by use of the PCR-Invader assay. Leuk Res 2011;35: 598–603.
- Hochhaus A, La Rosée P, Müller MC, et al. Impact of BCR-ABL mutations on patients with chronic myeloid leukemia. Cell Cycle 2011;10:250–260.
- Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009;27:6041–6051.
- Branford S, Melo JV, Hughes TP. Selecting optimal second- line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?Blood 2009;114:5426–5435.
- Castillo E, Al-Rajabi R, Pandya DM, et al. A pilot study of the combination of nilotinib and hyper-CVAD for Philadelphia chromosome positive acute lymphocytic leukemia and lymphoid blast crisis chronic myelogenous leukemia. Blood 2010;116:885–886.
- Ottmann OG, Larson RA, Kantarjian HM, et al. Phase II study of nilotinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia 2013; 27:1411–1413.
- Jabbour E, Kantarjian HM, Jones D, et al. Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. Blood 2008;112:4839–4842.
- Potenza L, Volzone F, Riva G, et al. Interferon-alpha may restore sensitivity to tyrosine-kinase inhibitors in Philadelphia chromosome positive acute lymphoblastic leukaemia with F317L mutation. Br J Haematol 2009;146:227–230.
- Chang BH, Willis SG, Stork L, et al. Imatinib resistant BCR- ABL1 mutations at relapse in children with Ph+ ALL: a Children's Oncology Group (COG) study. Br J Haematol 2012;157:507–510.